Juxtapid and Flatulence - a phase IV clinical study of FDA data

Summary:

Flatulence is reported as a side effect among people who take Juxtapid (lomitapide mesylate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Vitamin E, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Flatulence when taking Juxtapid. It is created by eHealthMe based on reports of 4,275 people who have side effects when taking Juxtapid from the FDA, and is updated regularly.

What is Juxtapid?

Juxtapid has active ingredients of lomitapide mesylate. eHealthMe is studying from 4,279 Juxtapid users. Check the latest studies of Juxtapid.

What is Flatulence?

Flatulence (flatus expelled through the anus) is found to be associated with 1,791 drugs and 1,889 conditions by eHealthMe. Check the latest studies of Flatulence.

On Apr, 29, 2026

4,275 people reported to have side effects when taking Juxtapid.
Among them, 281 people (6.57%) have Flatulence.

Among these 281 people:

* Approximation only. Some reports may have incomplete information.

Do you take Juxtapid and have Flatulence?

- Check whether Flatulence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Juxtapid:

Juxtapid (4,279 reports)

Flatulence treatments and more:

Flatulence (70,666 reports)

How severe was Flatulence and when was it recovered:

Flatulence in Juxtapid

Expand to all the drugs that have ingredients of lomitapide mesylate:

Flatulence and drugs with ingredients of lomitapide mesylate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Juxtapid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Flatulence:

Flatulence (1,791 drugs)

Browse all the conditions that are associated with Flatulence:

Flatulence (1,889 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lomitapide mesylate (the active ingredients of Juxtapid) and Juxtapid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.